{"filings":[{"id":721642,"accession_number":"0000914475-26-000029","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-05-28T20:01:33+00:00","items":["5.02","5.07"],"status":"ready","headline":"Neurocrine annual meeting re-elects three directors, approves equity plan and auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Class III directors Kevin C. Gorman, Gary A. Lyons, and Johanna Mercier with over 76M votes each.","Advisory vote on named executive officer compensation approved: 78.99M for, 5.67M against, 0.10M abstentions.","Stockholders approved Amended 2025 Equity Incentive Plan: 79.13M for, 5.57M against, 0.07M abstentions.","Ratified Ernst & Young as independent auditor for FY2026: 83.88M for, 6.17M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":483276,"accession_number":"0001193125-26-228013","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-05-18T13:04:56+00:00","items":["1.01","2.03","2.01","7.01","9.01"],"status":"ready","headline":"Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.","Merger completed May 18, 2026; Soleno becomes wholly owned subsidiary; shares to be delisted from Nasdaq.","VYKAT XR (diazoxide choline) is first approved therapy for hyperphagia in Prader-Willi syndrome (ages 4+).","Entered $1.0B senior secured revolving credit facility (5-yr); initial $600M drawn; SOFR + 1.125%-1.75% margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99724,"accession_number":"0000914475-26-000025","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).","Definitive agreement to acquire Soleno Therapeutics for $53.00 per share ($2.9B equity value), expected to close in Q2 2026.","Initiated Phase 2 study of NBI-1117570 (dual M1/M4 agonist) for schizophrenia and Phase 1 study of NBIP-’2118 (CRF2 agonist) for obesity.","Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion and total cash of $2.65 billion at March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":814500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99723,"accession_number":"0001193125-26-142904","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer for all Soleno shares at $53.00 cash each; no financing condition.","Offer requires >50% shares tendered, HSR clearance, no material adverse effect.","Termination fees: Soleno pays $95.25M for superior proposal; Neurocrine pays $141.5M for antitrust failure.","Soleno board recommends tender; CEO and former CFO (1.01% combined) signed support agreements.","Deal structured as tender offer followed by merger under Section 251(h) of DGCL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115891,"accession_number":"0000914475-26-000006","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).","INGREZZA Q4 sales $657.5M (+7% YoY); full year $2.51B (+9% YoY); 2026 guidance $2.7-2.8B.","CRENESSITY Q4 sales $135.3M (vs $1.7M YoY); full year $301.2M; 2,048 new patient start forms in FY.","GAAP diluted EPS Q4 $1.48 (vs $1.00); full year $4.67 (vs $3.29). Non-GAAP EPS Q4 $1.88 (vs $1.69).","Cash & marketable securities $2.54B at Dec 31, 2025; R&D and SG&A guidance provided for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":2860500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132302,"accession_number":"0000914475-25-000186","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neurocrine extends former CMO Eiry Roberts as Strategic Advisor through Dec 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roberts, former CMO, transitioned to Strategic Advisor effective June 2, 2025; term extended to Dec 31, 2026 (Amended Employment Agreement).","Base salary of $731,400 through Dec 31, 2025; future salary to be set by Compensation Committee thereafter.","Annual cash incentive bonus target 60% of base pay for 2025 and 2026, subject to corporate and individual goals.","Employment agreement expires Dec 31, 2026 unless earlier terminated; no severance upon natural expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132301,"accession_number":"0000914475-25-000180","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.","INGREZZA net sales $686.6M (+12% YoY) driven by record quarterly new and total prescriptions.","CRENESSITY launch generated $98.1M net sales with 540 new patient enrollment start forms.","FY2025 INGREZZA guidance reaffirmed at $2.50-2.55B; GAAP R&D $1.00-1.02B, SG&A $1.14-1.16B.","Initiated second Phase 3 trial for direclidine (schizophrenia); osavampator Phase 3 in MDD enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":2055000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148884,"accession_number":"0000914475-25-000157","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).","GAAP diluted EPS $1.06 (vs $0.63 Q2 2024); Non-GAAP diluted EPS $1.65 (vs $1.63).","INGREZZA 2025 net product sales guidance narrowed to $2.50-2.55B from $2.50-2.60B.","CRENESSITY: 664 new patient enrollment start forms in Q2; 76% reimbursement coverage for dispensed scripts.","Phase 3 study of valbenazine for adjunctive schizophrenia did not meet primary endpoint; safety consistent."],"consensus_eps_estimate":null,"consensus_eps_actual":1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1260100000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167788,"accession_number":"0000914475-25-000139","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.","Dr. Sanjay Keswani will succeed Dr. Roberts as Chief Medical Officer, effective June 2, 2025.","Dr. Roberts receives annual base salary of $731,400 and target bonus of 60% of base pay in new advisory role.","Outstanding equity awards continue vesting; severance terms substantially unchanged from prior agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167787,"accession_number":"0000914475-25-000120","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).","Advisory say-on-pay approved: ~78M for, ~6M against, ~1.7M abstentions.","2025 Equity Incentive Plan approved: ~72.6M for, ~12.9M against.","Amended and Restated 2018 ESPP approved: ~85.4M for, ~138K against.","Ratification of Ernst & Young as independent auditor for FY2025 approved: ~85M for, ~5.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167786,"accession_number":"0000914475-25-000099","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q1: INGREZZA $545M (+8%), CRENESSITY $14.5M; GAAP EPS $0.08; reaffirms FY25 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA net product sales $545M in Q1 2025, up 8% YoY; CRENESSITY sales $14.5M with 413 patient enrollment forms.","GAAP net income $7.9M ($0.08 EPS) vs $43.4M ($0.42) YoY; Non-GAAP net income $71.5M ($0.70) vs $124.8M ($1.20).","Reaffirmed 2025 INGREZZA net sales guidance of $2.5-$2.6B; total R&D guidance $960M-$1.01B GAAP.","Initiated Phase 3 registrational programs for osavampator in MDD and NBI-568 in schizophrenia.","Appointed Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025; authorized $500M share repurchase, $150M completed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":572600000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167785,"accession_number":"0000914475-25-000081","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Neurocrine appoints Sanjay Keswani as CMO effective June 2; Roberts transitions to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sanjay Keswani appointed CMO effective June 2, 2025; Eiry Roberts transitions to strategic advisory role after 7 years as CMO.","Keswani brings >20 yrs pharma/biotech experience; formerly CEO of ImmunoBrain, SVP at Roche, VP at BMS.","Roberts led INGREZZA expansion, crinecerfont approval as CRENESSITY, and Phase 2 studies for osavampator and NBI-1117568 now moving to registrational.","Roberts' retirement was announced in July 2023; she remained until replacement onboarded; orderly succession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185053,"accession_number":"0000914475-25-000034","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine reports Q4 INGREZZA sales $615M (+23% YoY); 2025 guidance $2.5-2.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA net product sales $2.3B for FY2024, up 26% YoY; Q4 sales $615M (+23% YoY).","CRENESSITY (crinecerfont) approved Dec 2024 for classic CAH; initial Q4 sales $2M.","Non-GAAP diluted EPS Q4 $1.69 vs $1.54 prior year; GAAP EPS $1.00 vs $1.44 (higher stock-based comp).","2025 INGREZZA sales guidance $2.5-2.6B; Phase 3 osavampator and NBI-568 starting H1 2025.","Completed $300M ASR program in Feb 2025, repurchased ~2.3M shares; cash $1.816B."],"consensus_eps_estimate":null,"consensus_eps_actual":3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":2355300000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185052,"accession_number":"0000914475-25-000006","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Neurocrine restructures Takeda deal for osavampator; gets global rights ex-Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neurocrine obtains exclusive worldwide development/commercialisation rights for osavampator except Japan, converts from profit-sharing to royalty-bearing license.","Takeda reacquires exclusive rights in Japan; royalties payable by each party on net sales in other's territory.","Tiered royalties to Takeda: mid-to-upper teens (US), low double-digits (ex-US) as % of net sales.","Phase 3 program for major depressive disorder expected to start H1 2025 after successful End-of-Phase 2 FDA meeting.","Amended agreement dated January 24, 2025; press release issued January 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201649,"accession_number":"0000914475-24-000229","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neurocrine Biosciences launches CRENESSITY for classic CAH at WAC ~$38,333/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CRENESSITY commercially available in U.S. for classic CAH (ages 4+); dispensed exclusively via PANTHERx Rare specialty pharmacy.","Wholesale acquisition cost ~$38,333/30-day supply for adults; ~$19,167 for pediatric patients <20 kg.","Company expects 90% of patients will have monthly copay of $12 or less through Neurocrine Access Support.","CAH-trained pharmacists available 24/7 via PANTHERx Rare; free support program for patients and providers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201648,"accession_number":"0000914475-24-000214","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine Biosciences launches $300M accelerated share repurchase with Goldman Sachs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into ASR agreement with Goldman Sachs & Co. to repurchase $300M of common stock.","On Nov 4, 2024, will pay $300M and receive 80% of shares based on Oct 31 closing price.","Final settlement expected in Q1 2025; additional shares or cash adjustments possible per terms.","Repurchase conducted under previously announced $300M board-authorized share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201647,"accession_number":"0000914475-24-000210","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q3 INGREZZA sales $613M (+26% YoY); raises FY2024 guidance; $300M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA net product sales $613M in Q3 2024, up 26% YoY; raised 2024 sales guidance to $2.30-$2.32B.","Total revenues $622.1M (+25% YoY); GAAP EPS $1.24 vs $0.82; Non-GAAP EPS $1.81 vs $1.54.","Board authorized $300M share repurchase plan; intends to enter accelerated share repurchase.","New CEO Kyle W. Gano appointed effective Oct 11, 2024; Phase 2 data for NBI-1117568 triggered $35M milestone.","Terminated licenses for luvadaxistat (CIAS) and NBI-827104; terminations expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1727600000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201646,"accession_number":"0000914475-24-000206","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neurocrine appoints Kyle Gano as CEO effective Oct 11, 2024; base salary $900k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyle Gano, Ph.D. named President and CEO effective October 11, 2024, under an amended employment agreement.","Annual base salary of $900,000; target cash bonus of 100% of base salary.","Promotion equity grants: $750k stock options, $300k RSUs, $450k PRSUs (total $1.5M).","Severance includes 1.5x salary plus bonus for non-CIC termination; 2x for CIC termination with full vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217637,"accession_number":"0000914475-24-000199","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Neurocrine's NBI-1117568 meets Phase 2 primary endpoint; 7.5-point PANSS reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["20 mg once-daily dose met primary endpoint: placebo-adjusted PANSS reduction of 7.5 points (p=0.011, effect size 0.61) at Week 6.","Dose also statistically significant on CGI-S, Marder positive and negative symptom scores.","NBI-’568 well tolerated; no weight gain vs placebo; GI events low; discontinuation rates similar to placebo.","Company plans to advance NBI-’568 into Phase 3 development in schizophrenia in early 2025.","Other doses (40 mg, 60 mg QD, 30 mg BID) did not reach statistical significance on primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217636,"accession_number":"0000914475-24-000180","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q2 INGREZZA sales $580M (+32% YoY); raises FY guidance; CEO Gorman to retire Oct 11","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA Q2 net product sales $580M (+32% YoY); FY 2024 guidance raised to $2.25-$2.3B.","GAAP net income $65M ($0.63 EPS); Non-GAAP net income $168.9M ($1.63 EPS), vs $125.7M ($1.25) YoY.","CEO Kevin Gorman to retire Oct 11, 2024; succeeded by Kyle Gano, current Chief Business Development Officer.","FDA granted Priority Review for crinecerfont in CAH; PDUFA Dec 29 (capsule) and Dec 30 (oral solution) 2024.","Top-line Phase 2 data for NBI-'568 (schizophrenia) and luvadaxistat (CIAS) on track for Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1105500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237540,"accession_number":"0001193125-24-148107","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Neurocrine CEO Kevin Gorman to retire Oct 11; Kyle Gano appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin C. Gorman, Ph.D. to retire as President and CEO effective October 11, 2024; will remain on the board.","Kyle Gano, Ph.D., current Chief Business Development and Strategy Officer, becomes President and CEO on same date.","Gano appointed to the board as a Class II director effective October 11, 2024.","Board size increased from 10 to 11 via bylaw amendment to accommodate Gano's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237539,"accession_number":"0000914475-24-000140","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Neurocrine stockholders elect directors, approve say-on-pay, amended equity plan, ratify EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four Class I directors elected: Rastetter, Morrow, Norwalk, Poon; each received >72M votes.","Advisory say-on-pay passed with ~80.3M for vs 4.3M against.","Amended 2020 Equity Incentive Plan approved (76.1M for, 9.5M against).","Ernst & Young ratified as auditor for FY2024 with 84.6M for, 5.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237538,"accession_number":"0000914475-24-000116","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q1: INGREZZA sales $506M (+23% YoY); GAAP EPS $0.42, non-GAAP EPS $1.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA net product sales $506M in Q1 2024 vs $411M in Q1 2023, up 23% year-over-year.","GAAP net income $43.4M ($0.42 diluted EPS) vs net loss $76.6M ($0.79 loss) in Q1 2023.","Non-GAAP net income $124.8M ($1.20 diluted EPS) vs net loss $49.5M ($0.51 loss) a year ago.","Total revenues $515.3M (+23% YoY); cash & equivalents $1.91B at quarter end.","FDA approved INGREZZA SPRINKLE; NDAs submitted for crinecerfont in congenital adrenal hyperplasia."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":515300000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255078,"accession_number":"0000914475-24-000033","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q4 INGREZZA sales $500M (+25% YoY); FY 2024 guidance $2.1-$2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income $147.7M ($1.44 diluted EPS) vs $89M ($0.88) in Q4 2022; non-GAAP EPS $1.54.","Full-year 2023 INGREZZA net product sales $1.84B (+29% YoY); total revenue $1.89B.","FY 2024 INGREZZA sales guidance $2.1–$2.2B; GAAP R&D $645–$675M, SG&A $930–$950M.","Patent litigation resolved; generic INGREZZA entry no earlier than March 2038.","Crinecerfont FDA submission for congenital adrenal hyperplasia expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1887100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272546,"accession_number":"0000914475-23-000078","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine settles all INGREZZA patent litigations; generic entry starts March 1, 2038","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Resolved patent litigation with Zydus; Zydus can sell generic INGREZZA from Oct 1, 2038 (or earlier under certain circumstances).","Prior settlements with Sandoz, Teva, and Lupin allow generic entry from March 1, 2038, subject to earlier triggers.","All ANDA-filing companies now settled, blocking generic competition until at least 2038, a significant IP win.","Settlements require FTC/DOJ review but are standard in Hatch-Waxman litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272545,"accession_number":"0000914475-23-000075","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine settles Lupin patent litigation; generic INGREZZA entry set for March 1, 2038","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settled with Lupin Limited and Lupin Pharmaceuticals; Lupin may sell generic INGREZZA starting March 1, 2038, or earlier under certain circumstances.","Prior settlements with Sandoz/Crystal and Teva also allow generic entry on March 1, 2038, subject to earlier launch conditions.","Remaining patent litigation against another ANDA filer is ongoing with trial scheduled for January 2, 2024.","Agreement will be submitted to FTC and DOJ as required by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272544,"accession_number":"0000914475-23-000072","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q3 INGREZZA sales $486M (+29% YoY); raises 2023 guidance to $1.82-1.84B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA Q3 net sales $486M (+29% YoY); total product sales $492M.","GAAP EPS $0.82; non-GAAP EPS $1.54. Cash & securities $1.55B.","INGREZZA 2023 net sales guidance raised to $1.82-1.84B.","FDA approved INGREZZA for Huntington's chorea; NDA accepted for oral granules (PDUFA Apr 30, 2024).","Phase 3 crinecerfont met primary endpoints in adult and pediatric CAH; Analyst Day Dec 5."],"consensus_eps_estimate":null,"consensus_eps_actual":1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1371900000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272543,"accession_number":"0000914475-23-000067","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine settles INGREZZA patent litigation; generic entry delayed to 2040","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Sandoz and Crystal grants generic INGREZZA license starting Feb 1, 2040, or earlier under certain conditions.","Patent litigation resolved for one ANDA filer; two other ANDA challenges remain pending with trial set for Jan 2, 2024.","Agreement to be submitted to FTC and DOJ as required by law.","INGREZZA is Neurocrine's drug for tardive dyskinesia and Huntington's chorea."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272542,"accession_number":"0000914475-23-000065","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neurocrine's crinecerfont Phase 3 pediatric CAH study meets primary, key secondary endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: statistically significant decrease in serum androstenedione at Week 4 vs placebo (p=0.0002).","Key secondary: significant reduction in daily glucocorticoid dose while maintaining androgen control at Week 28 vs placebo (p<0.0001).","About 30% of crinecerfont patients achieved reduction to physiologic GC dose vs 0% placebo.","Drug generally well-tolerated; common AEs: headache, fever, vomiting, URI, nasopharyngitis.","Data to support FDA submission in 2024, with EMA submission to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289376,"accession_number":"0000914475-23-000062","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neurocrine's crinecerfont meets Phase 3 endpoint in CAH adults; FDA submission planned for 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 CAHtalyst Adult study met primary endpoint: significant % reduction in daily glucocorticoid dose with androgen control (p<0.0001).","Key secondary endpoint met: significant decrease in androstenedione at Week 4 vs placebo (p<0.0001).","63% of crinecerfont patients achieved physiologic glucocorticoid dose vs 18% on placebo (p<0.0001).","Company to submit regulatory applications to FDA in 2024 and to EMA afterwards.","Crinecerfont generally well-tolerated; common AEs: fatigue, headache, coronavirus infection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289375,"accession_number":"0000914475-23-000056","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q2 beats with INGREZZA $440M (+26% YoY); raises 2023 sales forecast to $1.77-1.82B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $452.7M vs $378.2M YoY; GAAP EPS $0.95 vs loss of $0.18, non-GAAP EPS $1.25 vs $0.84.","INGREZZA net product sales $440M (26% YoY); record new patient starts in Q2.","2023 INGREZZA guidance raised to $1.77-1.82B from prior range; reaffirms R&D and SG&A expense guidance.","Cash, cash equivalents and marketable securities $1.32B at June 30, 2023; up from $1.29B at year-end 2022.","PDUFA date for valbenazine in Huntington's chorea set for Aug 20, 2023; four Phase 2/3 readouts expected in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":873100000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289374,"accession_number":"0000914475-23-000049","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neurocrine CMO Eiry Roberts to retire in 2025; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Eiry W. Roberts, M.D., notified Neurocrine of her plan to retire in 2025 for personal reasons.","Dr. Roberts will remain as CMO until her replacement is on-boarded; the company has initiated a search.","Her retirement is not due to any disagreement with Neurocrine's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289373,"accession_number":"0000914475-23-000047","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Neurocrine appoints Christine Poon to board; bylaws amended to increase board to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christine A. Poon appointed as Class I director effective July 11, 2023, term until 2024 annual meeting.","Poon receives $60k annual cash retainer and option for 16,375 shares (~$800k Black-Scholes) vesting over 3 years.","Board size increased from 9 to 10 via amendment to Section 3.2 of Bylaws.","Poon previously served as Vice Chairman of Johnson & Johnson and Dean at Ohio State Fisher College of Business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310180,"accession_number":"0001193125-23-149520","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Neurocrine shareholders approve amended 2020 equity plan and elect directors at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2020 Equity Incentive Plan with 84.95% of votes cast in favor.","Three Class III directors elected: Kevin Gorman, Gary Lyons, Johanna Mercier.","Advisory say-on-pay approved with 93.11% support; future say-on-pay votes to be held annually.","Ernst & Young ratified as independent auditor for FY2023 with 92.82% support.","No financial guidance or earnings reported; meeting focused on governance matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310179,"accession_number":"0000914475-23-000043","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q1 GAAP net loss $76.6M; INGREZZA sales $410M (+36% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["INGREZZA net sales $410M, up 36% YoY; guidance reiterated at $1.67-1.77B for FY2023.","GAAP net loss $76.6M ($0.79 loss per share) vs $13.9M income in Q1 2022.","Non-GAAP net loss $49.5M ($0.51 loss per share) vs $29.7M income in prior year.","Recorded $143.9M acquired IPR&D expense for Voyager gene therapy collaboration.","Valbenazine PDUFA for Huntington chorea set for Aug 20, 2023; top-line data from crinecerfont expected early Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":420400000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328842,"accession_number":"0000914475-23-000023","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine settles INGREZZA patent litigation with Teva; generic entry allowed Feb 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement grants Teva right to sell generic INGREZZA in the U.S. starting February 1, 2040, or earlier under certain conditions.","Agreement resolves ANDA patent litigation filed in District of Delaware; terms to be submitted to FTC and DOJ.","Patent litigation against three other ANDA filers for generic INGREZZA remains pending, trial scheduled for January 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328841,"accession_number":"0000914475-23-000016","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine closes collaboration with Voyager; pays $136M upfront, buys $39M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration Agreement with Voyager became effective Feb 21, 2023 after HSR waiting period expired.","Neurocrine paid Voyager ~$136M upfront and purchased 4,395,588 shares at $8.88/share for ~$39M.","Jude Onyia, Neurocrine's CSO, appointed to Voyager's board per Amended Investor Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328840,"accession_number":"0000914475-23-000013","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Neurocrine Biosciences adopts proxy access bylaw and updates stockholder nomination procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proxy access: stockholder(s) holding 3%+ for 3+ years can nominate up to 2 or 20% of directors.","Updated procedural requirements for nominations and proposals, including Rule 14a-19 compliance.","Nominees must provide updated disclosures as of the record date and 5 business days before the meeting.","Nominations disregarded if stockholder fails to comply with Rule 14a-19 or provide timely evidence.","Consent actions require notice to fix record date and use of independent inspectors to validate consents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328839,"accession_number":"0000914475-23-000005","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q4 INGREZZA sales $399M; guides FY23 INGREZZA $1.67-1.77B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 INGREZZA net product sales $399M (+33% YoY); full year $1.43B.","GAAP net income $89M ($0.88 diluted EPS) vs loss year-ago; non-GAAP net income $125M ($1.24 EPS).","FY2023 INGREZZA sales guidance $1.67-1.77B (tardive dyskinesia only); GAAP R&D $550-580M, SG&A $850-870M.","PDUFA date Aug 20, 2023 for valbenazine in Huntington chorea; crinecerfont registrational studies enrollment complete.","Acquired Diurnal Group (~$55M) Nov 2022; entered Voyager partnership for GBA1 gene therapy Jan 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1488700000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328838,"accession_number":"0000914475-23-000003","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neurocrine and Voyager form $175M upfront gene therapy collaboration for GBA1 and rare CNS targets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$175M upfront: ~$136M cash to Voyager plus $39M equity at $8.88/share (50% premium to 30-day VWAP).","Up to $1.5B in development milestones (GBA1 ≤$985M; each of three new CNS programs ≤$175M) plus commercial milestones & royalties.","Voyager can opt for 50/50 US co-dev/co-commercial on GBA1 after Phase 1 data; otherwise tiered royalties (low-double-digit to 20% US).","Three new rare CNS gene therapy programs leverage Voyager's TRACER capsids; Neurocrine funds all development costs.","Jude Onyia, Ph.D. (Neurocrine CSO), to join Voyager's board effective closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346495,"accession_number":"0000914475-22-000055","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q3 2022: INGREZZA sales $376M, GAAP EPS $0.69; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 INGREZZA net product sales $376M (+31% YoY); TRx ~68,600 (+32% YoY).","GAAP net income $68.5M ($0.69 diluted EPS); non-GAAP net income $106.7M ($1.08 EPS).","Total revenue $387.9M, up 31% from $296.0M in Q3 2021.","Raised 2022 INGREZZA sales guidance to $1.400-$1.425B; R&D & SG&A guidance reaffirmed.","Acquired Diurnal Group plc for ~£48.3M (~$56M); sNDA for valbenazine in Huntington chorea submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1076700000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362878,"accession_number":"0000914475-22-000050","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Neurocrine to acquire Diurnal Group for £48.3M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquiring entire issued share capital of Diurnal for ~£48.3M (~$56.5M) in an all-cash transaction.","Transaction conditional on approval by Diurnal shareholders and other customary closing conditions.","Neurocrine expects deal to accelerate establishment of UK clinical development and commercial capabilities.","Announcement made under Rule 2.7 of the UK City Code on Takeovers and Mergers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362877,"accession_number":"0000914475-22-000043","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q2 INGREZZA sales $350M (+32%), raises FY guidance to $1.35-1.40B; essential tremor Phase 2a fails","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $16.9M ($0.18 loss per diluted share) vs net income $42.3M in Q2 2021, largely due to $70M debt extinguishment loss.","Non-GAAP net income $82.1M ($0.84 EPS) vs $70.1M ($0.72); INGREZZA net product sales $350M, up 32% YoY.","Raised 2022 INGREZZA net product sales guidance to $1.35-1.40B from prior $1.30-1.35B; GAAP R&D guidance $415-450M.","Phase 2a study of NBI-827104 in essential tremor did not meet endpoints; company discontinues development in that indication.","Received $20M milestone from MTPC for DYSVAL launch in Japan; FDA cleared IND for NBI-1117568 (M4 agonist for schizophrenia) Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":688800000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382557,"accession_number":"0000914475-22-000035","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine repurchases $31.4M of 2.25% Convertible Notes due 2024 for $41.5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchased ~$31.4M principal of 2024 Convertible Notes for ~$41.5M including accrued interest.","Transactions entered on May 31, 2022; closing expected June 2, 2022.","Repurchases are in addition to those disclosed in May 25, 2022 Form 8-K.","Company notes repurchases could affect common stock market price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382556,"accession_number":"0000914475-22-000032","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neurocrine Biosciences repurchases $179.4M of convertible notes, reduces debt by ~60% over two years","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchased $179.4M principal of 2.25% Convertible Senior Notes due 2024 for ~$224M cash plus stock-price-based component and accrued interest.","After repurchase, $201.8M principal remains outstanding; reduced from initial $517.5M.","CFO states debt reduction of ~60% over two years aims to minimize shareholder dilution.","Repurchases expected to close by June 14, 2022 under separate private agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382555,"accession_number":"0000914475-22-000028","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Neurocrine shareholders approve equity plan amendments, elect directors at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class II directors elected: Richard Pops, Shalini Sharp, Stephen Sherwin; each received >72M votes.","Advisory vote on executive compensation passed with 92.76% support.","Amended and restated 2020 Equity Incentive Plan and ESPP approved (89% and 99.6% of votes cast, respectively).","Ernst & Young LLP ratified as independent auditor for fiscal 2022 with 93.28% approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382554,"accession_number":"0000914475-22-000021","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q1: INGREZZA sales $303M (+32% YoY), GAAP EPS $0.14, reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $303M (+32% YoY); total revenue $310.6M incl $5.6M collaboration revenue.","GAAP net income $13.9M ($0.14 diluted EPS) vs $32.1M ($0.33) in Q1 2021.","Non-GAAP net income $29.7M ($0.30 diluted EPS) vs $48.8M ($0.50) prior year.","Cash and marketable securities $1.2B; reiterates 2022 INGREZZA sales guidance $1.25-$1.35B.","Positive Phase 3 valbenazine data in Huntington chorea; sNDA filing expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":310600000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400447,"accession_number":"0000914475-22-000009","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine reports 2021 INGREZZA sales of $1.1B, guides 2022 sales $1.25-1.35B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue FY 2021 $1.13B (+8% YoY); INGREZZA net sales $1.09B (+10% YoY).","GAAP net income $89.6M ($0.92 diluted EPS); non-GAAP net income $185.8M ($1.90 diluted EPS).","Q4 2021 GAAP net loss $7.3M ($0.08 loss per share) due to $100M Sosei Heptares upfront fee.","2022 INGREZZA guidance $1.25-1.35B (+20% YoY midpoint); minimal federal cash taxes expected in 2022.","Phase III KINECT-HD valbenazine met primary endpoint; sNDA for Huntington chorea planned H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":1133500000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400446,"accession_number":"0000914475-22-000004","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Biosciences reports preliminary Q4 2021 INGREZZA sales ~$301M, FY ~$1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 INGREZZA net sales ~$301M ($296M inventory-adjusted), up 25% YoY; prescriptions up 32% YoY.","Full-year 2021 INGREZZA net sales ~$1.1B.","Full-year 2022 INGREZZA sales guidance to be provided on Feb 11, 2022 earnings call.","Pipeline: sNDA for valbenazine in Huntington chorea in 2H 2022; Phase 2 data for NBI-827104 mid-2022.","Company now has 13 mid-to-late-stage clinical programs with data readouts over the next two years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":1133500000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419404,"accession_number":"0000914475-21-000064","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neurocrine Biosciences' license with Heptares effective; $100M upfront due","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration and License Agreement with Heptares Therapeutics becomes effective Dec 22, 2021 after HSR clearance.","Neurocrine to pay Heptares $100M upfront within ten days of effective date.","Agreement originally entered Nov 22, 2021; HSR waiting period expired Dec 22, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15668704167.503183,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-23T23:59:59+00:00|419404"}